Spectral AI, Inc. (NASDAQ:MDAI – Free Report) – Equities researchers at HC Wainwright increased their FY2027 earnings estimates for Spectral AI in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.63 for the year, up from their previous estimate of $0.53. HC Wainwright currently has a “Buy” rating and a $3.50 target price on the stock. The consensus estimate for Spectral AI’s current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Spectral AI’s FY2028 earnings at $0.46 EPS.
Spectral AI (NASDAQ:MDAI – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $7.48 million for the quarter, compared to analysts’ expectations of $6.00 million.
Spectral AI Stock Down 11.3 %
MDAI opened at $1.34 on Friday. The firm has a market cap of $24.80 million, a price-to-earnings ratio of -1.01 and a beta of 0.48. Spectral AI has a fifty-two week low of $0.82 and a fifty-two week high of $3.72. The company’s 50-day moving average price is $1.26 and its 200 day moving average price is $1.54.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Murchinson Ltd. bought a new position in shares of Spectral AI in the first quarter valued at approximately $85,000. Forum Financial Management LP bought a new position in shares of Spectral AI in the second quarter valued at approximately $51,000. Finally, Virtu Financial LLC bought a new position in shares of Spectral AI in the first quarter valued at approximately $38,000. 67.08% of the stock is currently owned by institutional investors.
Spectral AI Company Profile
Spectral AI, Inc, an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers.
Featured Articles
- Five stocks we like better than Spectral AI
- What Are Dividends? Buy the Best Dividend Stocks
- L3Harris: Positioned for Gains With Trump’s Defense Policies
- Roth IRA Calculator: Calculate Your Potential Returns
- Is First Solar’s Earnings Drop a Golden Buying Opportunity?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Take-Two Interactive’s 2024 Comeback: New Highs Expected in 2025
Receive News & Ratings for Spectral AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral AI and related companies with MarketBeat.com's FREE daily email newsletter.